<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechanisms and treatment regimens for non-cytotoxic drug extravasations&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechanisms and treatment regimens for non-cytotoxic drug extravasations<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Mechanisms and treatment regimens for non-cytotoxic drug extravasations<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Primary mechanism of injury</td> <td class="subtitle1">Drug</td> <td class="subtitle1">Other mechanism(s)</td> <td class="subtitle1">Toxicity</td> <td class="subtitle1">Compresses*</td> <td class="subtitle1">Potential antidote(s) for peripheral catheter extravasation</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Acidic</td> <td>Amiodarone</td> <td>NI</td> <td>Necrosis</td> <td>Cold or warm</td> <td>None</td> </tr> <tr> <td>Gentamicin</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Metronidazole</td> <td>NI</td> <td>Necrosis, gangrene</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Nicardipine</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Promethazine</td> <td>NI</td> <td>Necrosis</td> <td>Cold or warm</td> <td>None</td> </tr> <tr class="divider_bottom"> <td>Vancomycin</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>Hyaluronidase may be considered based on mechanism of injury<sup>¶</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="6">Alkaline</td> <td>Acyclovir</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Aminophylline</td> <td>Hyperosmotic</td> <td>Ischemia</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Furosemide</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Ganciclovir</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Phenobarbital</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr class="divider_bottom"> <td>Phenytoin</td> <td>Hyperosmotic, precipitation</td> <td>Necrosis, purple glove syndrome</td> <td>Warm</td> <td>Hyaluronidase<sup>¶</sup> or topical nitroglycerin<sup>Δ</sup> may be considered based on mechanism of injury</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Chemical</td> <td>Amphotericin</td> <td>NI</td> <td>Phlebitis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Digoxin</td> <td>NI</td> <td>Inflammation, apoptosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td>Foscarnet</td> <td>NI</td> <td>Phlebitis, arteritis</td> <td>Cold</td> <td>None</td> </tr> <tr class="divider_bottom"> <td>Propofol</td> <td>NI</td> <td>Necrosis</td> <td>Cold</td> <td>None</td> </tr> <tr> <td class="divider_bottom" rowspan="11">Hyperosmotic (osmolarity &gt;290 mOsm/L) tissue damage may resemble compartment syndrome</td> <td>Contrast media, radiographic</td> <td>Pressure effect of large volume</td> <td>Pressure necrosis</td> <td>Cold or as per radiologist</td> <td>None</td> </tr> <tr> <td>Calcium solutions</td> <td>Vasoconstriction, calcinosis</td> <td>Necrosis, calcinosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td rowspan="2"> <p>Hyaluronidase<sup>¶</sup></p> Severe forms of cutaneous calcinosis have been treated with sodium thiosulfate infusions, eg, once weekly for 3 weeks</td> </tr> <tr> <td>Dextrose ≥10%</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> </tr> <tr> <td>Magnesium sulfate</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>None</td> </tr> <tr> <td>Mannitol &gt;5%</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>Hyaluronidase<sup>¶</sup></td> </tr> <tr> <td>Nafcillin</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>Hyaluronidase<sup>¶</sup></td> </tr> <tr> <td>Parenteral nutrition/amino acids solutions</td> <td>Acidic</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>Hyaluronidase<sup>¶</sup></td> </tr> <tr> <td>Potassium chloride &gt;40 mEq/L</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>Hyaluronidase<sup>¶</sup></td> </tr> <tr> <td>Sodium bicarbonate</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>Hyaluronidase<sup>¶</sup></td> </tr> <tr> <td>Sodium chloride &gt;1%</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>None</td> </tr> <tr class="divider_bottom"> <td>Valproate sodium</td> <td>NI</td> <td>Necrosis</td> <td>Warm if hyaluronidase used; cold may be used if hyaluronidase is not used</td> <td>None</td> </tr> <tr> <td rowspan="7">Vasoconstriction (causing local ischemia)</td> <td>Dobutamine</td> <td>NI</td> <td>Necrosis</td> <td>Warm</td> <td>2% topical nitroglycerin ointment<sup>Δ</sup> and/or terbutaline administered subcutaneously may be considered</td> </tr> <tr> <td>Dopamine</td> <td>Acidic</td> <td>Necrosis</td> <td>Warm</td> <td rowspan="5"> <p><strong>Preferred:</strong> Phentolamine<sup>◊</sup></p> <p><strong>Alternative:</strong> 2% topical nitroglycerin ointment<sup>Δ</sup></p> Terbutaline administered subcutaneously has been used if phentolamine is unavailable</td> </tr> <tr> <td>Epinephrine</td> <td>Acidic</td> <td>Necrosis</td> <td>Warm</td> </tr> <tr> <td>Methylene blue</td> <td>NI</td> <td>Cellular toxicity</td> <td>Warm</td> </tr> <tr> <td>Norepinephrine</td> <td>Acidic</td> <td>Necrosis</td> <td>Warm</td> </tr> <tr> <td>Phenylephrine</td> <td>Acidic</td> <td>Necrosis</td> <td>Warm</td> </tr> <tr> <td>Vasopressin</td> <td>Acidic</td> <td>Necrosis</td> <td>Warm</td> <td>None documented; 2% topical nitroglycerin ointment<sup>Δ</sup> followed by phentolamine<sup>◊</sup> may be considered based on mechanism of injury</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Recommendations are based on case descriptions, experience at some leading centers, or extrapolated according to mechanism of injury. Consult local protocols if available.</li>
<li>Antidotes listed are potential adjuncts to general extravasation injury care (ie, stop infusion immediately, do not flush line, leave catheter/needle in place to aspirate, elevate limb, evaluate as clinically indicated [eg, immediate surgery consultation]). Mild extravasations of small volume are generally amenable to supportive care and observation. Refer to topic discussion.</li>
</ul></div><div class="graphic_footnotes"><p>NI: none identified.</p>
<p>* Dry cold or warm compresses should be applied to affected area for 20 minutes once every 4 to 6 hours for 1 to 2 days after removal of the catheter/needle and limb elevation. Cold compresses reduce pain, inflammation, and localize the vesicant potentially facilitating administration of an antidote. Application of warmth causes vasodilation and may facilitate dispersion and absorption.</p>
<p>¶ Hyaluronidase, administered as multiple subcutaneous injections around affected area, enhances dispersion and absorption of extravasated medications. Ideally, administer within 1 hour of extravasation; some benefit may be derived within 12 hours. If hyaluronidase is used, avoid cold compresses as they oppose its action; warm compresses are preferred.</p>
<p>Δ Alternative, if phentolamine is unavailable, is topical nitroglycerin 2%, applied as 1 inch (2.5 cm) strip over affected area, should be applied within 1 hour of extravasation. Avoid use of warm compresses if topical nitroglycerin is used. Local injection of terbutaline has also been tried as an antidote for vasopressors if phentolamine is unavailable.</p>
◊ Phentolamine, administered as multiple subcutaneous injections around affected area, antagonizes alpha-adrenergic receptors stimulated by catecholamine extravasation. Ideally administer as soon as possible; some benefit may be derived within 12 hours.</div><div class="graphic_reference">References:
<ol>
<li>David V, Christou N, Etienne P, et al. Extravasation of Noncytotoxic Drugs. Ann Pharmacother 2020; 54:804.</li>
<li>Le A, Patel S. Extravasation of noncytotoxic drugs: a review of the literature. Ann Pharmacother 2014; 48:870.</li>
<li>Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy 2014; 34:617.</li>
</ol>
<p class="extra_spacing_top">Adapted from: Valentin D, Christou N, Etienne P, et al. Extravasation of Noncytotoxic Drugs. Ann Pharmacother 2020; 54:804.</p></div><div id="graphicVersion">Graphic 127371 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
